Ixekizumab
Treatment for Ankylosing Spondylitis
Typical Dosage: 160mg subcutaneous (2x80mg) at week 0, then 80mg every 4 weeks
Effectiveness
69%
Safety Score
60%
Clinical Trials
8
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
160mg subcutaneous (2x80mg) at week 0, then 80mg every 4 weeks
Time to Effect
2-4 weeks
Treatment Duration
Lifetime
Evidence Quality
HIGHNumber Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
91%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40,000
Monitoring:$500
Side Effect Mgmt:$500
Total Annual:$41,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$150,000/QALY
QALYs Gained
1.2
Outcome-Based Costs
Cost per Responder
$56,944
Cost per Remission
$128,125
Comparison vs Adalimumab
Cost Difference
+$10,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Ixekizumab Outcomes
for Ankylosing Spondylitis
Efficacy Outcomes
Overall Effectiveness
+69%
Response Rate
+72%
Remission Rate
+32%
Common Side Effects
Nasopharyngitis
+15%
Upper respiratory tract infections
+12%
Injection site reactions
+10%
Conjunctivitis
+3%
Oral candidiasis
+1%
Sources:
Active Clinical Trials
3 active trials recruiting for Ixekizumab in Ankylosing Spondylitis
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
NCT04527380ACTIVE NOT RECRUITINGPHASE3
101 participants
INTERVENTIONAL
Rosario, Argentina +42 more
Started: Apr 13, 2021
Korean College of Rheumatology Biologics and Targeted Therapy Registry
NCT01965132RECRUITING
10K participants
OBSERVATIONAL
Seoul, South Korea
Started: Dec 1, 2012
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
NCT07138898NOT YET RECRUITINGPHASE2
80 participants
INTERVENTIONAL
New York, United States
Started: Sep 1, 2025
Completed Clinical Trials
4 completed trials for Ixekizumab in Ankylosing Spondylitis
A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis
NCT04285229COMPLETEDPHASE3
147 participants
INTERVENTIONAL
Bengbu, China +18 more
Started: Apr 10, 2020
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis
NCT02696798COMPLETEDPHASE3
316 participants
INTERVENTIONAL
Phoenix, United States +98 more
Started: Apr 12, 2016
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis
NCT02696785COMPLETEDPHASE3
341 participants
INTERVENTIONAL
Phoenix, United States +27 more
Started: May 2, 2016
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis
NCT02757352COMPLETEDPHASE3
303 participants
INTERVENTIONAL
Phoenix, United States +108 more
Started: Aug 2, 2016